Posted by Michael Wonder on 08 Dec 2023
Adaptimmune completes submission of rolling biologics license application to US FDA for afami-cel for the treatment of advanced synovial sarcoma
6 December 2023 - First BLA for an engineered T-cell therapy for solid tumours submitted to US FDA.
Adaptimmune Therapeutics today announced the completion of the submission of its rolling biologics license application to the US FDA for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma.
